Self-collected HPV tests: what the guidelines actually say

Self-collected HPV tests are real, FDA-approved, and available in the United States — but where you can use one still depends on the product. Since May 2024 the FDA has permitted patients to collect their own vaginal swab in a health care setting, and in May 2025 it approved a prescription at-home collection device. National screening guidance is still catching up.

Cervical cancer screening looks for human papillomavirus, or HPV, a common virus that can cause the cell changes that sometimes lead to cervical cancer. For decades the only way to get a screening sample was a clinician using a speculum. That is beginning to change, and the change is aimed at the people routine screening has always had the hardest time reaching. What follows is information, not medical advice; decisions about your own screening belong with you and your clinician.

What is a self-collected HPV test?

A self-collected HPV test is one in which you insert a soft swab into the vagina yourself, and the sample is sent to a laboratory for high-risk HPV testing. High-risk HPV testing is a molecular test that looks for the viral types most strongly associated with cervical cancer, rather than examining cells under a microscope the way a Pap test does.

That distinction matters more than it first appears. A vaginal self-swab is not the same specimen as a clinician-collected cervical sample. It works for HPV testing, which detects the virus where it is shedding. It is not used for cytology — the Pap test — which requires cells taken from the cervix itself.

Where can you actually do this right now?

Two different things were approved, a year apart, and they are easy to confuse. In May 2024 the FDA expanded the instructions for use of two existing tests — Becton, Dickinson and Co.'s Onclarity HPV Assay and Roche Molecular Systems' cobas HPV Test — to allow patient self-collection. Per the FDA's May 2024 announcement, the expanded instructions "allow for the patient to self-collect a vaginal swab in a health care setting."

The agency framed that narrowly: self-collection is permitted in a health care setting when the patient and the health care provider determine that it is not possible for the clinician to collect a cervical specimen. The National Cancer Institute noted in 2024 that those settings can include primary care offices, urgent care, pharmacies, and mobile clinics.

The at-home option came later and is separate. Teal Health announced on May 9, 2025 that the FDA had approved its Teal Wand, which the company describes as the first at-home vaginal self-collection device for cervical cancer screening in the United States. By the company's own account it is a prescription device for people aged 25 to 65 at average risk, and the collected sample is run on the same Roche cobas HPV test used in clinics. Those are the manufacturer's statements about its own product, not an independent assessment.

How accurate is a self-collected sample?

The short answer, according to the U.S. Preventive Services Task Force's December 2024 draft recommendation, is that self-collection of an HPV test for screening "has similar accuracy to clinician-collected tests." That draft has not been finalized, and a draft is a proposal open for comment, not settled national guidance.

It is worth being precise about what "similar accuracy" covers: the comparison is for detecting high-risk HPV. It is not a claim about cytology, which self-collection does not provide.

Evidence is still accumulating. The National Cancer Institute reported in 2024 that its Self-collection for HPV Testing to Improve Cervical Cancer Prevention, or SHIP, trial had launched earlier that year specifically to study self-collected samples, with results not yet available. Teal Health has cited its own SELF-CERV study, reporting that self-collected samples detected cervical precancer 96% of the time; that figure comes from the company and should be read as a manufacturer's claim about its own device rather than as independent confirmation.

What do the current guidelines say?

Guidance is in an unusual state: the most widely cited recommendation predates self-collection, while newer federal guidance has already embraced it. The USPSTF's current final recommendation dates to August 21, 2018, and the Task Force's own page notes the topic is being updated. That 2018 statement does not include self-collection as a screening option.

Meanwhile, the Health Resources and Services Administration accepted updated Women's Preventive Services Initiative recommendations published in the Federal Register on January 5, 2026. For women aged 30 to 65 at average risk, that guideline states that patient-collected high-risk HPV testing "is an appropriate method and should be offered as an option."

Here is how the main screening strategies compare under current U.S. guidance. This is a summary of what the issuing bodies recommend, not a recommendation from this publication.

The CDC's cervical cancer screening page, last updated February 26, 2025, still lists the HPV test, the Pap test, and co-testing without describing self-collection. Guidance from different bodies genuinely differs right now, and this is a U.S.-only picture as of August 2026.

Coverage lags guidance by design. Under the Federal Register notice, non-grandfathered health plans must cover the updated services without cost-sharing for plan years beginning one year after January 5, 2026 — which for most plans means 2027. Whether a self-collected test is covered for you today depends on your plan and your state.

What happens if a self-collected test comes back positive?

A positive HPV result is not a cancer diagnosis. It means a high-risk HPV type was detected, and that further evaluation is needed to find out whether any cell changes are present.

The National Cancer Institute noted in 2024 that additional health care provider visits may be needed to determine whether precancerous cells are present and whether a removal procedure is warranted. The January 2026 Federal Register guideline is explicit that "additional testing may be required to complete the screening process," and names cytology, extended genotyping, colposcopy, biopsy, and pathologic evaluation as steps that may follow when clinically indicated.

In practical terms, a self-collected test can start the screening process but does not finish it. The CDC's guidance on abnormal results is straightforward: an abnormal result usually does not mean you have cervical cancer, and it is important to follow up with your doctor promptly.

Who is this most likely to help?

The case for self-collection rests less on accuracy than on access. The National Cancer Institute reported in 2024 that roughly 30% of eligible people in the United States do not receive recommended cervical cancer screening, and that about half of new cervical cancer cases occur in people who were never screened or were screened inadequately. Around 11,500 cervical cancers are diagnosed in the U.S. each year, per the same NCI reporting.

The USPSTF's 2024 draft makes a similar point, noting that self-collected HPV screening appears particularly effective at reaching historically underscreened populations — while also observing that most of the evidence for increased uptake came from home-based self-collection rather than clinic-based settings. That is a real gap between where the evidence was generated and where the FDA's 2024 approval applies.

When to talk to a clinician

Screening is for people without symptoms. If you have symptoms, screening is not the right tool, and the timeline is different.

Talk to a clinician promptly about bleeding between periods, bleeding after sex, bleeding after menopause, or unusual vaginal discharge or pelvic pain. These are not signs that you have cancer, and they have many benign explanations, but they warrant evaluation rather than a screening test.

Also worth a conversation: whether you are due for screening, which strategy fits your age and history, and whether self-collection is available where you receive care. If a speculum exam has been a barrier for you, that is worth raising directly. If you have had an abnormal result before, a hysterectomy, a weakened immune system, or a history of cervical precancer, the standard intervals may not apply to you.

For a related health news perspective, read Self-Care Strategies for Women Entrepreneurs: Mental Health Tips.